Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

37,839 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A gene expression signature of RAS pathway dependence predicts response to PI3K and RAS pathway inhibitors and expands the population of RAS pathway activated tumors.
Loboda A, Nebozhyn M, Klinghoffer R, Frazier J, Chastain M, Arthur W, Roberts B, Zhang T, Chenard M, Haines B, Andersen J, Nagashima K, Paweletz C, Lynch B, Feldman I, Dai H, Huang P, Watters J. Loboda A, et al. Among authors: zhang t. BMC Med Genomics. 2010 Jun 30;3:26. doi: 10.1186/1755-8794-3-26. BMC Med Genomics. 2010. PMID: 20591134 Free PMC article.
Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.
Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP. Andersen JN, et al. Among authors: zhang t. Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065. Sci Transl Med. 2010. PMID: 20686178
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies.
O'Neil J, Benita Y, Feldman I, Chenard M, Roberts B, Liu Y, Li J, Kral A, Lejnine S, Loboda A, Arthur W, Cristescu R, Haines BB, Winter C, Zhang T, Bloecher A, Shumway SD. O'Neil J, et al. Among authors: zhang t. Mol Cancer Ther. 2016 Jun;15(6):1155-62. doi: 10.1158/1535-7163.MCT-15-0843. Epub 2016 Mar 16. Mol Cancer Ther. 2016. PMID: 26983881
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
Guertin AD, O'Neil J, Stoeck A, Reddy JA, Cristescu R, Haines BB, Hinton MC, Dorton R, Bloomfield A, Nelson M, Vetzel M, Lejnine S, Nebozhyn M, Zhang T, Loboda A, Picard KL, Schmidt EV, Dussault I, Leamon CP. Guertin AD, et al. Among authors: zhang t. Mol Cancer Ther. 2016 Aug;15(8):1998-2008. doi: 10.1158/1535-7163.MCT-15-0950. Epub 2016 Jun 2. Mol Cancer Ther. 2016. PMID: 27256377
Evidence of mTOR Activation by an AKT-Independent Mechanism Provides Support for the Combined Treatment of PTEN-Deficient Prostate Tumors with mTOR and AKT Inhibitors.
Zhang W, Haines BB, Efferson C, Zhu J, Ware C, Kunii K, Tammam J, Angagaw M, Hinton MC, Keilhack H, Paweletz CP, Zhang T, Winter C, Sathyanarayanan S, Cheng J, Zawel L, Fawell S, Gilliland G, Majumder PK. Zhang W, et al. Among authors: zhang t. Transl Oncol. 2012 Dec;5(6):422-9. doi: 10.1593/tlo.12241. Epub 2012 Dec 1. Transl Oncol. 2012. PMID: 23323157 Free PMC article.
Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.
Di Cosimo S, Sathyanarayanan S, Bendell JC, Cervantes A, Stein MN, Braña I, Roda D, Haines BB, Zhang T, Winter CG, Jha S, Xu Y, Frazier J, Klinghoffer RA, Leighton-Swayze A, Song Y, Ebbinghaus S, Baselga J. Di Cosimo S, et al. Among authors: zhang t. Clin Cancer Res. 2015 Jan 1;21(1):49-59. doi: 10.1158/1078-0432.CCR-14-0940. Epub 2014 Oct 15. Clin Cancer Res. 2015. PMID: 25320355 Free PMC article. Clinical Trial.
MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
Booher RN, Hatch H, Dolinski BM, Nguyen T, Harmonay L, Al-Assaad AS, Ayers M, Nebozhyn M, Loboda A, Hirsch HA, Zhang T, Shi B, Merkel CE, Angagaw MH, Wang Y, Long BJ, Lennon XQ, Miselis N, Pucci V, Monahan JW, Lee J, Kondic AG, Im EK, Mauro D, Blanchard R, Gilliland G, Fawell SE, Zawel L, Schuller AG, Strack P. Booher RN, et al. Among authors: zhang t. PLoS One. 2014 Oct 7;9(10):e108371. doi: 10.1371/journal.pone.0108371. eCollection 2014. PLoS One. 2014. PMID: 25289887 Free PMC article.
Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW, Kluk M, Laskey J, Haines BB, Moskaluk C, Zawel L, Fawell S, Gilliland G, Zhang T, Kremer BE, Knoechel B, Bernstein BE, Pear WS, Liu XS, Aster JC, Sathyanarayanan S. Stoeck A, et al. Among authors: zhang t. Cancer Discov. 2014 Oct;4(10):1154-67. doi: 10.1158/2159-8290.CD-13-0830. Epub 2014 Aug 7. Cancer Discov. 2014. PMID: 25104330 Free PMC article.
Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, Zhang T, Tyminski E, Yuan J, Kohl NE, Richon VM, Van der Ploeg LH, Carroll PM, Draetta GF, Look AT, Strack PR, Winter CG. Rao SS, et al. Among authors: zhang t. Cancer Res. 2009 Apr 1;69(7):3060-8. doi: 10.1158/0008-5472.CAN-08-4295. Epub 2009 Mar 24. Cancer Res. 2009. PMID: 19318552
Identification of potential pharmacological and toxicological targets differentiating structural analogs by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines.
Hartley DP, Dai X, Yabut J, Chu X, Cheng O, Zhang T, He YD, Roberts C, Ulrich R, Evers R, Evans DC. Hartley DP, et al. Among authors: zhang t. Pharmacogenet Genomics. 2006 Aug;16(8):579-99. doi: 10.1097/01.fpc.0000220561.59972.7a. Pharmacogenet Genomics. 2006. PMID: 16847427
37,839 results
You have reached the last available page of results. Please see the User Guide for more information.